Edwin Reisz Sells 16,755 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 16,755 shares of Aveanna Healthcare stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $8.36, for a total transaction of $140,071.80. Following the completion of the sale, the insider owned 1,355,329 shares of the company’s stock, valued at approximately $11,330,550.44. This trade represents a 1.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Aveanna Healthcare Price Performance

AVAH opened at $8.08 on Friday. The company has a market capitalization of $1.69 billion, a P/E ratio of 22.44 and a beta of 2.06. The company has a 50-day moving average of $8.92 and a 200-day moving average of $7.51. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23. Aveanna Healthcare Holdings Inc. has a 1-year low of $3.67 and a 1-year high of $10.32.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings results on Monday, May 22nd. The company reported $0.04 EPS for the quarter. The business had revenue of $450.53 million during the quarter. Aveanna Healthcare had a negative return on equity of 143.55% and a net margin of 3.29%. Equities analysts expect that Aveanna Healthcare Holdings Inc. will post -0.06 EPS for the current fiscal year.

Institutional Trading of Aveanna Healthcare

A number of large investors have recently modified their holdings of the company. Banque Transatlantique SA acquired a new position in Aveanna Healthcare during the 1st quarter valued at about $25,000. Quantbot Technologies LP bought a new stake in shares of Aveanna Healthcare during the second quarter valued at approximately $43,000. Lion Street Advisors LLC acquired a new position in shares of Aveanna Healthcare during the third quarter worth approximately $89,000. Jump Financial LLC bought a new position in Aveanna Healthcare in the 1st quarter worth approximately $59,000. Finally, Diversified Trust Co acquired a new stake in Aveanna Healthcare in the 2nd quarter valued at approximately $57,000. Institutional investors and hedge funds own 87.96% of the company’s stock.

More Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
• Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
• Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
• Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
• Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AVAH. Jefferies Financial Group raised their price objective on Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Truist Financial increased their target price on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a report on Friday, November 7th. Zacks Research lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, October 20th. William Blair initiated coverage on shares of Aveanna Healthcare in a research report on Monday, December 8th. They set an “outperform” rating for the company. Finally, Raymond James Financial reissued an “outperform” rating and issued a $13.00 target price on shares of Aveanna Healthcare in a report on Friday, December 5th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.69.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.